Vera Therapeutics (VERA) Return on Capital Employed (2021 - 2026)
Vera Therapeutics (VERA) posted Return on Capital Employed of 60.56% for Q1 2026, down 9.94% on a QoQ basis from 55.09% in Q4 2025, and down 2893.0% year-over-year from 2.17% in Q1 2025.
Vera Therapeutics (VERA) Return on Capital Employed (2021 - 2026) Analysis & Trends
Vera Therapeutics' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 60.56% for Q1 2026.
- Quarterly Return on Capital Employed fell 2893.0% year-over-year to 60.56% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 60.56% (down 2893.0% YoY) and the FY2025 annual result came in at 49.16%, down 632.0% from the prior year.
- Return on Capital Employed was 60.56% for Q1 2026 at Vera Therapeutics, down from 55.09% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 30.07% in Q2 2024 and bottomed at 85.92% in Q4 2022.
- A 5-year average of 51.98% and a median of 53.38% in 2025 frame the typical range for Return on Capital Employed.
- Peak annual rise in Return on Capital Employed reached 6547 bps in 2022, while the deepest fall reached 4279 bps in 2022.
- Vera Therapeutics' Return on Capital Employed stood at 85.92% in 2022, then advanced by 23 bps to 66.55% in 2023, then soared by 48 bps to 34.34% in 2024, then tumbled by 60 bps to 55.09% in 2025, then slipped by 10 bps to 60.56% in 2026.
- Business Quant data shows VERA's Return on Capital Employed at 60.56% in Q1 2026, 55.09% in Q4 2025, and 53.38% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Vera Therapeutics | 2.60 Bn | 2.60 Bn | - | -60.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -60.56% |
| Dec 31, 2025 | -55.09% |
| Sep 30, 2025 | -53.38% |
| Jun 30, 2025 | -42.09% |
| Mar 31, 2025 | -31.63% |
| Dec 31, 2024 | -34.34% |
| Sep 30, 2024 | -40.76% |
| Jun 30, 2024 | -30.07% |
| Mar 31, 2024 | -36.01% |
| Dec 31, 2023 | -66.55% |
| Sep 30, 2023 | -67.53% |
| Jun 30, 2023 | -63.83% |
| Mar 31, 2023 | -71.53% |
| Dec 31, 2022 | -85.92% |
| Sep 30, 2022 | -59.53% |
| Jun 30, 2022 | -40.05% |
| Mar 31, 2022 | -44.74% |
| Dec 31, 2021 | -43.13% |
| Sep 30, 2021 | -66.81% |
| Jun 30, 2021 | -80.55% |